Understanding Semaglutide (Ozempic) in CKD and T2D

Welcome back to Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives! The US Food and Drug Administration (FDA) approval of semaglutide 1.0 (Ozempic) for reducing the risk of kidney disease progression in type 2 diabetes marks a significant advance in the treatment landscape. To celebrate the approval and breakdown what the latest semaglutide approval means for clinicians and patients with type 2 diabetes, cohosts Diana Isaacs, PharmD, an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and co-director of Endocrine Disorders in Pregnancy at the Cleveland Clinic, and Natalie Bellini, DNP, program director of Diabetes Technology at University Hospitals Diabetes and Metabolic Care Center, convened for a special edition episode of Diabetes Dialogue. Key Timestamps 00:00:00 Introduction 00:00:18 Semaglutide's FDA approval for T2D and CKD 00:03:21 ADA Standards of Care referenced GLP-1 RAs as first-line options 00:04:55 Side effects of semaglutide and GLP-1s 00:06:22 Will semaglutide be prioritized over other GLP-1s for T2D and CKD? 00:09:57 Will these benefits be replicated in patients with obesity without T2D? 00:11:19 Semaglutide data at Kidney Week 2024 00:12:29 Outro

There are no comments yet.

Please log in to write the first comment.